
- Telehealth Visits

Alyssa Reddy, MD
Pediatric NeurologyDirector, UCSF Neurofibromatosis Program


Alyssa Reddy, MD
Pediatric NeurologyDirector, UCSF Neurofibromatosis Program- Telehealth Visits
On this page
About me
Dr. Alyssa Reddy is a pediatric neurologist with expertise in treating children who have tumors of the central nervous system. She has more than 20 years of experience in diagnosing and managing brain tumors and other neurologic disorders. She cares for children and young adults in both the clinic and the hospital.
Reddy directs UCSF's program in neurofibromatosis, a genetic disorder in which tumors form on nerves and can affect many elements of the body, including skin, bones and senses such as hearing. She aims to provide patients with compassionate care as well as access to cutting-edge treatment.
Reddy's research has focused mainly on improving long-term survival and quality of life for children with brain tumors. She believes these goals are best accomplished through a collaborative approach from a diverse team of scientists and health care providers with the ability to offer new therapies through clinical trials.
After earning her medical degree from the University of Alabama at Birmingham School of Medicine, Reddy completed a residency in pediatrics at the Children's of Alabama. She completed fellowships in child neurology at Children's of Alabama and in neuro-oncology at the Children's National Medical Center. She is a member of the Children's Oncology Group, Society for Neuro-Oncology and Child Neurology Society.
In college, Reddy participated in track and cross-country, where she met her husband, Michael. They have three children, Alex, Rachael and Brooks, who each live in a different state. Reddy enjoys spending time with family, traveling and being outdoors.
Education
Board Certification
- Neurology w/ Special Qualification in Child Neurology - General, American Board of Psychiatry and Neurology
Fellowship
- Pediatric Neurology, University of Alabama School of Medicine - GME
Residency
- Pediatrics, University of Alabama School of Medicine - GME
Internship
- Pediatrics, University of Alabama School of Medicine - GME
School
- MD, University of Alabama School of Medicine
Academic Title
- Health Sciences Clinical Professor
Care Keywords
Services
- Pediatric Neurology
Locations
Provider Research Listing
Browse clinical trials and publications by this provider
Clinical trials
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade GliomaOpens in a new window
Recruiting
The Kaplan-Meier method will be used to estimate EFS which is defined as the interval from randomization to first occurrence of clinical or radiographic diseas...A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCTOpens in a new window
Recruiting
Will be measured by the number of progressions or deaths within 2 years of enrollment for the cohort treated with whole ventricular + spinal canal irradiation...A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)Opens in a new window
Recruiting
Defined as the highest dose of selinexor in combination with standard of care radiation therapy that does not cause unacceptable side effects.A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing LossOpens in a new window
Recruiting
Will estimate the number and percentage of patients with >= grade 2 hearing loss using the society of pediatric oncology (SIOP) scale (defined as hearing thres...
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.
